Clinical Trials Browser

Phase 2/3 × Neoplasm Recurrence, Local × Clear all

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local